S

Sanofi

Global pharma company; vaccines and R&D

FFE Business Partner Lead GenMed

Full-TimeUpdated on 10/23/2026Deadline 12/1/26
No salary listed
Expert
Bachelor's, Master's, MBA, PhD
Shanghai, China
In Person
Business & StrategyBusiness Operations

About the job

Requirements
  • A bachelor's degree is required; an advanced degree such as a Master's, PhD, or MBA is preferred.
  • At least 6 years of FFE, field force management, or business consulting experience in healthcare, pharmaceutical, or related industries, preferably in a multinational company; specialty care experience is strongly preferred.
  • Project management experience is required; change management experience involving FFE transformation or evolution is preferred.
  • Knowledge of pharmaceutical field force models, territory alignment principles, and target-setting guidelines.
  • Solid knowledge of FFE tools, processes, performance-tracking methodologies, and analytical frameworks, with an in-depth understanding of field team operations and the China pharmaceutical industry.
  • Strong communication skills to influence stakeholders and collaborate with partner departments.
  • Business judgment to identify priority performance bottlenecks.
  • Strong analytical skills to conduct a wide range of analyses independently and collaboratively.
  • Ability to develop solutions within complex business environments and processes.
  • Ability to navigate cross-team dynamics and drive influence and impact.
  • Ability to learn and adapt to a rapidly changing industry environment and practices.
  • Ability to work under pressure and potentially overtime to deliver high-quality work on time.
  • Good command of written and spoken English.
Responsibilities
  • Advise GBU/BU general managers on field force strategy and execution excellence by creating and delivering data-driven analytical solutions and end-to-end statistical approaches to business problems.
  • Improve field force execution excellence and productivity with GBU/BU teams through analytical support and advice.
  • Provide insights and recommendations on GBU/BU execution planning and build an execution-tracking system with the business units.
  • Manage field force planning processes for GBU/BU.
  • Drive the transition to continuous customer engagement by leveraging digital tools and new technologies.
  • Collaborate with GBU/BU, other CE teams, and supporting functions to continuously improve FFE processes and activities.
  • Support GBU/BUs with field force sizing and deployment plans aligned with business objectives.
  • Provide methodologies, templates, tools, and analytical support for territory management, including target hospital identification and potential analysis, workload estimation, territory alignment, target setting, and listing planning.
  • Apply insights and experience to ensure field force planning fits the China business context and aligns with business strategy.
  • Lead quarterly and yearly field force planning cycles, including territory alignment and target setting, ensuring timely and high-quality delivery.
  • Coordinate between GBU/BU and the FFE Incentive team on incentive design to align business priorities with incentives.
  • Work with GBU/BU to design and improve execution frameworks for customer profiling, segmentation and targeting, customer interaction planning (calls, remote engagement, and events), and objective setting.
  • Design execution tracking mechanisms and reports, and monitor execution with GBU/BU management teams.
  • Provide GBU/BU management with insights and recommendations on execution status, gaps, and proposed actions.
  • Drive continuous execution-model transitions with GBU/BU and work with digital and omnichannel teams inside and outside GBU/BU.
  • Manage FFE dashboards for GBU/BU, including design, data collection, production, and delivery.
  • Work with marketing and field force teams to translate business needs into analytical requirements.
  • Provide routine and ad hoc analyses for GBU/BU management on execution excellence, productivity improvement, and resource allocation.
  • Lead or coordinate key FFE projects with GBU/BU, including customer segmentation and field force sizing.
  • Manage day-to-day FFE operational support for GBU/BU.
  • Coordinate with GBU/BU and other teams to improve field force operating systems for efficiency and effectiveness.
  • Manage the FFE Analysis Team to ensure quality support for GBU/BU.
  • Be responsible for the professional development of the FFE Analysis Team.
Desired Qualifications
  • Specialty care experience is strongly preferred.
  • Change management experience involving FFE transformation or evolution is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...